Gilead Sciences
GILD
Gilead Sciences (GILD) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- −$6.75
- EPS estimate
- −$7.26
- EPS surprise
- +7.03%
- Revenue surprise
- +5.47%
- Revenue
- $7.8B
- Revenue estimate
- $7.4B
- Reported
- Aug 4, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 4, 2026 | −$7.26 | −$6.75 | +7.03% | $7.8B | SEC |
| Q1 2026 | May 7, 2026 | $1.91 | $2.03 | +6.31% | $7.0B | SEC |
| Q4 2025 | Feb 10, 2026 | $1.81 | $1.86 | +2.76% | $7.9B | SEC |
| Q3 2025 | Oct 30, 2025 | $2.13 | $2.47 | +15.85% | $7.8B | SEC |
| Q2 2025 | Aug 7, 2025 | $1.96 | $2.01 | +2.55% | $7.1B | SEC |
| Q1 2025 | Apr 24, 2025 | $1.78 | $1.81 | +1.66% | $6.7B | SEC |
| Q4 2024 | Feb 11, 2025 | $1.74 | $1.90 | +9.35% | $7.6B | SEC |
| Q3 2024 | Nov 6, 2024 | $1.53 | $2.02 | +32.03% | $7.5B | SEC |
| Q2 2024 | Aug 8, 2024 | $1.61 | $2.01 | +25.05% | $7.0B | SEC |
| Q1 2024 | Apr 25, 2024 | −$1.49 | −$1.32 | +11.60% | $6.7B | SEC |
| Q4 2023 | Feb 6, 2024 | $1.76 | $1.72 | −2.18% | $7.1B | SEC |
| Q3 2023 | Nov 7, 2023 | $1.92 | $2.29 | +19.49% | $7.1B | SEC |
| Q2 2023 | Aug 3, 2023 | $1.64 | $1.34 | −18.42% | $6.6B | SEC |
| Q1 2023 | Apr 27, 2023 | $1.52 | $1.37 | −10.07% | $6.4B | SEC |
| Q4 2022 | Feb 2, 2023 | $1.52 | $1.67 | +10.02% | $7.4B | SEC |
| Q3 2022 | Oct 27, 2022 | $1.43 | $1.90 | +33.28% | $7.0B | — |
| Q2 2022 | Aug 2, 2022 | $1.52 | $1.58 | +4.23% | $6.3B | — |
| Q1 2022 | Apr 28, 2022 | $1.80 | $2.12 | +17.50% | $6.6B | SEC |
| Q4 2021 | Feb 1, 2022 | $1.59 | $0.69 | −56.69% | $7.2B | — |
| Q3 2021 | Oct 28, 2021 | $1.76 | $2.65 | +50.79% | $7.4B | — |
Quarterly revenue
Frequently asked questions
When did Gilead Sciences (GILD) last report earnings?
Gilead Sciences last reported on Aug 4, 2026, covering fiscal Q2 2026.
Did GILD beat earnings estimates?
Yes. Gilead Sciences reported EPS of −$6.75 for Q2 2026 against a −$7.26 estimate — a 7.03% beat.
How much revenue did GILD report last quarter?
Gilead Sciences reported $7.8B in revenue for Q2 2026, against a consensus estimate of $7.4B.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.